Teva's Copaxone , and Sandoz's Glatopa are both glatiramer products, also a disease-modifying agent for RRMS. Glatopa is a substitutable generic version of Copaxone and only available in the 20 mg/mL dose. The generic agent can save patients thousands of dollars. Common side effects with glatiramer include: injection site reactions, flushing, chest pain, or post-injection reaction (anxiety, chest pain, heart palpitations, shortness of breath, throat constriction, flushing). Post injection side effects typically last 15-30 minutes, subside without treatment, and have no known long-term effects.
In clinical trials (Studies 1, 2, and 3), a total of 1212 patients with relapsing forms of multiple sclerosis received GILENYA mg. This included 783 patients who received GILENYA mg in the 2-year placebo-controlled trials (Studies 1 and 3) and 429 patients who received GILENYA mg in the 1 year active-controlled trial (Study 2). The overall exposure in the controlled trials was equivalent to 1716 person-years. Approximately 1000 patients received at least 2 years of treatment with GILENYA mg. In all clinical studies, including uncontrolled extension studies, the exposure to GILENYA mg was approximately 4119 person-years.